Followers | 270 |
Posts | 15407 |
Boards Moderated | 1 |
Alias Born | 03/28/2013 |
Tuesday, June 20, 2017 6:05:52 PM
Source: Business Wire
Biogen Inc. (NASDAQ:BIIB) today announced it will report second quarter 2017 financial results and a strategic update on Tuesday, July 25, 2017, before the financial markets open.
Following the release of the financials, the Company will host a live webcast with Biogen management from 8:00-9:30 am ET. To access the live webcast, please go to the investor relations section of Biogen’s website at www.biogen.com/investors. Following the live webcast, an archived version of the call will be available at the same URL.
About Biogen
Through cutting-edge science and medicine, Biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. For more information, please visit www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170620005997/en/
Biogen
Karen Jewell, 781-464-2442
Investor Relations
Recent BIIB News
- UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024 • GlobeNewswire Inc. • 09/24/2024 05:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2024 11:31:32 AM
- Biogen Board Appoints Two New Independent Directors • GlobeNewswire Inc. • 09/12/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 10:00:08 AM
- Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA • GlobeNewswire Inc. • 09/04/2024 11:30:34 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/03/2024 05:00:40 PM
- Leqembi® (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain • PR Newswire (US) • 08/22/2024 09:10:00 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 08/16/2024 10:40:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:30:57 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 08:11:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 10:55:02 AM
- Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen • PR Newswire (US) • 07/31/2024 01:00:00 PM
- New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC • GlobeNewswire Inc. • 07/30/2024 09:15:17 PM
- New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at The Alzheimer's Association International Conference (AAIC) 20 • PR Newswire (US) • 07/30/2024 09:00:00 PM
- Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union • GlobeNewswire Inc. • 07/26/2024 11:20:38 AM
- Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor • Business Wire • 07/24/2024 10:30:00 AM
- The Gross Law Firm Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB • PR Newswire (US) • 07/17/2024 09:45:00 AM
- Biogen Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - BIIB • PR Newswire (US) • 07/16/2024 08:00:00 AM
- Biogen Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - BIIB • PR Newswire (US) • 07/12/2024 09:45:00 AM
- July 22, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against BIIB • PR Newswire (US) • 07/03/2024 09:45:00 AM
- Biogen Completes Acquisition of Human Immunology Biosciences • GlobeNewswire Inc. • 07/02/2024 01:16:51 PM
- Nike Stock Drops 14% in Pre-Market; Nokia Acquires Infinera for $2.3 Billion, and More News • IH Market News • 06/28/2024 10:50:25 AM
- The Gross Law Firm Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 06/28/2024 09:45:00 AM
- “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China • GlobeNewswire Inc. • 06/27/2024 11:39:36 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM